Upon Approval. Within ten (10) Business days of receipt by Auxilium, its Affiliate or Sublicensee of the first Regulatory Approval from the FDA for an Exercised Indication, Auxilium shall make the following milestone payments to BTC on a per Indication basis: $[**] [**] $[**] [**] $[**] [**] $[**] [**] $[**] [**]
Appears in 3 contracts
Sources: Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc), Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc), Development and License Agreement (Auxilium Pharmaceuticals Inc)
Upon Approval. Within ten (10) Business days of receipt by Auxilium, its Affiliate or Sublicensee Auxilium of the first Regulatory Approval from the FDA for an Exercised Indication, Auxilium shall make the following milestone payments to BTC on a per Indication basis: $[**] [**] $[**] [**] $[**] [**] $[**] [**] $[**] [**]Each Additional Indication
Appears in 2 contracts
Sources: Development and License Agreement (Auxilium Pharmaceuticals Inc), Development and License Agreement (Auxilium Pharmaceuticals Inc)
Upon Approval. Within ten (10) Business days of receipt by Auxilium, its Affiliate or Sublicensee of the first Regulatory Approval from the FDA for an Exercised Indication, Auxilium shall make the following milestone payments to BTC on a per Indication basis: $[***] $[***] [***] $[***] $[***] $[**] [**] $[**] [**] $[**] [**]
Appears in 1 contract
Sources: Development and License Agreement (Biospecifics Technologies Corp)